{"id":"placebo-with-enzalutamide","safety":{"commonSideEffects":[{"rate":"34","effect":"Fatigue"},{"rate":"20","effect":"Hot flashes"},{"rate":"21","effect":"Diarrhea"},{"rate":"30","effect":"Musculoskeletal pain"},{"rate":"12","effect":"Headache"},{"rate":"8","effect":"Hypertension"},{"rate":"0.5","effect":"Seizures"}]},"_chembl":{"chemblId":"CHEMBL1082407","moleculeType":"Small molecule","molecularWeight":"464.44"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Enzalutamide competitively inhibits androgen receptor signaling by preventing ligand binding and blocking nuclear accumulation of the receptor. This mechanism is effective in castration-resistant prostate cancer where alternative androgen synthesis pathways may be active. The drug reduces proliferation of androgen-dependent cancer cells and can induce apoptosis.","oneSentence":"Enzalutamide is an androgen receptor inhibitor that blocks the binding and nuclear translocation of androgens, thereby suppressing androgen-driven prostate cancer cell growth.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:29:06.209Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic castration-resistant prostate cancer"},{"name":"Non-metastatic castration-resistant prostate cancer"},{"name":"Metastatic hormone-sensitive prostate cancer"}]},"trialDetails":[{"nctId":"NCT06629779","phase":"PHASE3","title":"A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-10-22","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":900},{"nctId":"NCT04191096","phase":"PHASE3","title":"Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-12","conditions":"Metastatic Hormone-Sensitive Prostate Cancer","enrollment":1251},{"nctId":"NCT03395197","phase":"PHASE3","title":"Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2017-12-18","conditions":"mCRPC","enrollment":1054},{"nctId":"NCT04821622","phase":"PHASE3","title":"Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2021-05-12","conditions":"Prostate Cancer","enrollment":599},{"nctId":"NCT07028853","phase":"PHASE3","title":"This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-09-28","conditions":"Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer","enrollment":1000},{"nctId":"NCT05726292","phase":"PHASE2","title":"A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-01-06","conditions":"Prostate Cancer, Prostate Adenocarcinoma","enrollment":90},{"nctId":"NCT05700903","phase":"PHASE4","title":"Contributions to Hypertension With Androgen Deprivation Therapy","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2023-09-20","conditions":"Androgen Deprivation Therapy, Prostate Cancer, Hypertension","enrollment":10},{"nctId":"NCT04076059","phase":"PHASE3","title":"An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Astellas Pharma China, Inc.","startDate":"2019-09-11","conditions":"Metastatic Hormone Sensitive Prostate Cancer","enrollment":180},{"nctId":"NCT04455750","phase":"PHASE3","title":"A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2021-10-14","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8","enrollment":61},{"nctId":"NCT02003924","phase":"PHASE3","title":"Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-10-31","conditions":"Nonmetastatic Castration-Resistant Prostate Cancer, Prostate Cancer, Cancer of the Prostate","enrollment":1401},{"nctId":"NCT06120491","phase":"PHASE3","title":"Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-11-21","conditions":"Metastatic Castration-Sensitive Prostate Cancer","enrollment":1800},{"nctId":"NCT02203695","phase":"PHASE2","title":"Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2015-03-28","conditions":"Adenocarcinoma of the Prostate","enrollment":86},{"nctId":"NCT02677896","phase":"PHASE3","title":"A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2016-03-09","conditions":"Metastatic Hormone Sensitive Prostate Cancer","enrollment":1150},{"nctId":"NCT02294461","phase":"PHASE3","title":"An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2014-04-23","conditions":"Progressive Metastatic Prostate Cancer","enrollment":395},{"nctId":"NCT04934722","phase":"PHASE3","title":"Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-05-25","conditions":"Metastatic Hormone-Sensitive Prostate Cancer","enrollment":186},{"nctId":"NCT02007512","phase":"PHASE2","title":"Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-12-16","conditions":"Breast Cancer","enrollment":247},{"nctId":"NCT03834493","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-07-28","conditions":"Prostatic Neoplasms","enrollment":1244},{"nctId":"NCT02319837","phase":"PHASE3","title":"Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2014-12-17","conditions":"Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate","enrollment":1068},{"nctId":"NCT02288247","phase":"PHASE3","title":"A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2014-12-01","conditions":"Metastatic Castration Resistant Prostate Cancer","enrollment":688},{"nctId":"NCT03851640","phase":"PHASE3","title":"A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).","status":"RECRUITING","sponsor":"Hinova Pharmaceuticals Inc.","startDate":"2019-04-12","conditions":"MCRPC","enrollment":417},{"nctId":"NCT02528643","phase":"PHASE2","title":"A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2015-11-09","conditions":"Advanced Hepatocellular Carcinoma","enrollment":165},{"nctId":"NCT04094519","phase":"PHASE1","title":"A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate Cancer","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2020-01-27","conditions":"Prostate Cancer","enrollment":24},{"nctId":"NCT05627752","phase":"PHASE2, PHASE3","title":"Docetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC Stage","status":"UNKNOWN","sponsor":"Zhongnan Hospital","startDate":"2024-06-01","conditions":"Prostate Cancer, Castrate Resistant Prostate Cancer","enrollment":120},{"nctId":"NCT01995513","phase":"PHASE4","title":"Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-10-22","conditions":"Prostate Cancer","enrollment":509},{"nctId":"NCT05771896","phase":"PHASE3","title":"Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC","status":"WITHDRAWN","sponsor":"GenesisCare USA","startDate":"2023-09","conditions":"Metastatic Prostate Cancer","enrollment":""},{"nctId":"NCT03437941","phase":"PHASE1, PHASE2","title":"Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With mCRPC","status":"COMPLETED","sponsor":"Corcept Therapeutics","startDate":"2017-12-15","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":39},{"nctId":"NCT04237584","phase":"PHASE3","title":"A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients","status":"TERMINATED","sponsor":"MANA RBM","startDate":"2020-06-30","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":23},{"nctId":"NCT02407054","phase":"PHASE2","title":"A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-04-29","conditions":"Prostate Cancer Metastatic","enrollment":142},{"nctId":"NCT03704519","phase":"PHASE1","title":"Imaging Study to Compare Effects of Darolutamide and Enzalutamide With Respect to Placebo on the Blood Flow in the Brain in Healthy Male Volunteers.","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-10-23","conditions":"Cerebrovascular Circulation","enrollment":26},{"nctId":"NCT01212991","phase":"PHASE3","title":"A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-09-16","conditions":"Prostate Cancer","enrollment":1717},{"nctId":"NCT00974311","phase":"PHASE3","title":"Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-09-30","conditions":"Castration-Resistant Prostate Cancer","enrollment":1199},{"nctId":"NCT02929576","phase":"PHASE3","title":"Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer","status":"WITHDRAWN","sponsor":"Pfizer","startDate":"2016-09","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT02525068","phase":"PHASE2","title":"A Study of Enzalutamide in Combination With AZD5363 in Patients With mCRPC","status":"UNKNOWN","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2014-12","conditions":"Adenocarcinoma of the Prostate","enrollment":136},{"nctId":"NCT01605227","phase":"PHASE3","title":"Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100","status":"COMPLETED","sponsor":"Exelixis","startDate":"2012-07","conditions":"Prostate Cancer, Castration Resistant Prostate Cancer, Pain","enrollment":1028},{"nctId":"NCT02225093","phase":"PHASE1","title":"A Study to Evaluate How Daily Dosing With Enzalutamide Affects the Metabolism of Caffeine and Dextromethorphan in Men With Prostate Cancer","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2013-10-02","conditions":"Pharmacokinetics of Dextromethorphan, Pharmacokinetics of Caffeine, Prostate Cancer","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":240,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo with enzalutamide","genericName":"Placebo with enzalutamide","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Enzalutamide is an androgen receptor inhibitor that blocks the binding and nuclear translocation of androgens, thereby suppressing androgen-driven prostate cancer cell growth. Used for Metastatic castration-resistant prostate cancer, Non-metastatic castration-resistant prostate cancer, Metastatic hormone-sensitive prostate cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}